Skip to main content

Sound Advice: July 22, 2026

Ignore drug commercials that use the word “support”

In drug commercials, support usually means the drug is being promoted for a condition where it helps manage symptoms or improve daily functioning, not that it cures the disease. In practice, it often means “this medication can support your treatment plan,” while the ad still has to present risks and benefits in a balanced way and stay consistent with the FDA-approved label.

If you heard the word in a specific commercial, it can also be used more loosely to mean:

  • “Supports relief” or “supports control” of symptoms.
  • “Supports your body’s natural process,” which is marketing language rather than a precise medical claim.
  • “Supportive care,” meaning the drug is part of overall treatment, not the whole solution.

A simple example: a commercial might say a drug “supports healthy sleep” or “supports joint comfort,” which sounds gentle and helpful, but the real question is what the approved indication is and what benefits and side effects are actually shown in the labeling.

What's the difference between support and approved by the FDA?

“Support” usually means the product may help with a symptom or part of a condition, but it is not a formal regulatory claim. “Approved by the FDA” means the FDA has reviewed the product’s evidence and approved it for a specific use, with labeling that spells out what it is proven to do and what risks it has.

A simple way to think about it:

  • Support = a softer, broader claim that may suggest benefit.
  • FDA-approved = an official determination for a specific indication, based on evidence submitted to the FDA.

In drug commercials, “supports” can also be used for help-seeking or broader wellness-style messaging, while FDA approval applies to the actual drug and its approved prescribing information. So if a commercial says a product “supports” something, that does not automatically mean the FDA has approved that exact claim in the way it has approved a prescription drug’s labeled use.

A good rule: “support” tells you the ad is implying benefit; “FDA-approved” tells you the government has cleared a specific medical use with defined evidence and warnings.

 

Comments

Post a Comment

Popular posts from this blog

Sound Advice: July 16, 2025

Fixed annuities are poor investments Fixed annuities are often criticized as poor investments for several reasons, despite their reputation for providing stable, predictable income.  Here are the key drawbacks and concerns:   High Fees and Commissions Internal Fees:  Fixed annuities can carry a range of fees, including administrative charges, mortality expense risk fees, and rider fees. These can add up to 2%–4% per year, significantly eroding returns over time. Commissions:  Sales agents and financial advisors often receive high commissions for selling annuities—sometimes as much as 5%–8% of the invested amount. This creates a financial incentive for advisers to recommend them, even when they may not be the best fit for the client. Comparison to Other Investments:  Mutual funds and ETFs typically have much lower fees and commissions, making them more cost-effective for long-term growth. Limited Growth a...
Post a Comment
Read more

Sound Advice: October 8, 2025

How many investors have outperformed the stock market over the last 20 years? Very few investors have outperformed the stock market over the past 20 years.   Data shows that only about 6% to 8% of actively managed equity funds in the U.S. beat the market over this period, with the vast majority—over 90%—underperforming the S&P 500 or equivalent broad indexes. Percentage of Investors Beating the Market Only 8% of equity funds investing in large companies managed to outperform the market over a recent 20-year span. About 94% of all domestic funds underperformed the S&P 1500 Composite Index from 2005-2024. Over shorter timeframes (5-10 years), typically fewer than 15-20% of fund managers beat the S&P 500, and performance persistence is rare. Why It Is Rare The S&P 500’s high returns have proven immensely difficult to beat, especially as indexing has become popular and markets have ...
Post a Comment
Read more

Sound Advice: November 10, 2025

The stock market indexes seem to be dominated by a handful of tech stocks, but how is the average stock doing? As of late October/early November 2025, the S&P 500 index excluding the Magnificent Seven stocks (the "Other 493") has delivered a modest year-to-date return of approximately 5.3% to 5.4%. That’s barely more than one third of the performance of the full, market-capitalization-weighted S&P 500 index, which was up around 15.1% to 16% over the same period.  (The Magnificent Seven stocks are Alphabet (Google), Amazon, Apple, Meta (Facebook), Microsoft, Nvidia, and Tesla.) Index Concentration and Market Breadth The S&P 500 Equal Weight Index underperformed the standard, cap-weighted S&P 500 by about 12% in 2024, reflecting the gap between the top performing giants and the rest of the market. Only sectors like utilities, industrials, real estate, and energy outperformed their cap-weighted peers, while tech and consumer-focused sectors were ...
Post a Comment
Read more